Results demonstrated here align with emerging data on selpercatinib’s efficacy across diverse RET-altered tumors, including NSCLC, colorectal cancer, salivary gland cancer, pancreatic adenocarcinoma and glioblastoma, thereby indicating its broad applicability5,10–12. Here, RET is linked to salivary gland cancer.